The Hemochron® Response RxDx® heparin and protamine dosing system

Journal of Extra-Corporeal Technology

Volumn 36, Issue 3, 2004, Pages 258-262

  Jaryno, Stacy A ^a   Zucker, Marcia L ^a,b   LaDuca, Frank M ^a  

^a International Technidyne Corporation   (United States)

^b NONE   (United States)

Author keywords

Cardiac surgery; Hemochron Response RxDx; Heparin; Protamine

Indexed keywords

HEPARIN; INFUSORIAL EARTH; KAOLIN; PROTAMINE; ANTICOAGULANT AGENT; HEPARIN ANTAGONIST;

ADULT; AGED; ANTICOAGULATION; AORTA VALVE REPLACEMENT; BLOOD CLOTTING TIME; BLOOD VOLUME; CALCULATOR; COMPUTER PROGRAM; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DOSE CALCULATION; DOSE RESPONSE; FEMALE; GENDER; HEIGHT; HUMAN; MALE; MITRAL VALVE REPLACEMENT; WEIGHT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMPARATIVE STUDY; COMPUTER ASSISTED DRUG THERAPY; DRUG EFFECT; HEART SURGERY; HOSPITAL INFORMATION SYSTEM; MICROCOMPUTER; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARDIAC SURGICAL PROCEDURES; COMPUTERS, HANDHELD; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; PROTAMINES; SOFTWARE;

EID: 7544238479     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Majerus PW, Broze GJ, Miletich JP, Tollefson DM. Anticoagulant, thrombolytic and antiplatelet drugs. In: Gilman AG, Rall TW, Niles AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill, Inc., 1993;1311-31.
2. Horrow JC. Protamine: A review of its toxicity. Anesth Analg. 1985; 64:348-61.
3. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36-45.
4. DeLaria GA, Tyner JJ, Hayes CL, Armstrong BW. Heparin-protamine mismatch: A controllable factor in bleeding after open-heart surgery. Arch Surg. 1994;129:945-51.
5. Rivard D, Thompson S. Demonstration of heparin reversal with protamine administration using an automated protamine dose assay: A comparison of two methods. J Extra Corpor Technol. 1988:80: 63-6.
6. LaDuca FM, Zucker ML, Walker CE. Assessing heparin neutralization following cardiac surgery: sensitivity of thrombin time-based assays versus protamine titration methods. Perfusion. 1999;14:181-7.
7. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet. 1986;8: 307-10.
8. El Rouby S, Rinehart K, Zucker ML, LaDuca FM. A handheld personal digital assistant (PDA) program for the HEMOCHRON® RxDx® heparin and protamine dosing system. J Extra Corpor Technol. 2003;35:212-7.
9. Jobes DR, Etzioni DA, Stesis LH, et al. Cost-effective management of heparin/protamine in cardiopulmonary bypass; Analysis by type of surgery. Anesthesiology. 1996;85:A147.
10. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism. 1956;5:328-45.
11. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation: I- Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69: 674-84.